Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
In this review, we focus primarily on describing locoregional and systemic management strategies for isolated locoregional recurrences manifesting as isolated first-failure events following mastectomy or breast-conserving therapy.
An oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.
Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab.
In this case, we examine a 49-year-old man with widespread metastatic sclerotic bone lesions. What is your diagnosis?
Dr. Manson discusses the results of the recently published VITAL study that tested whether vitamin D or omega-3 supplements could be effective for primary prevention of cancer and cardiovascular disease.